Cagrilintide is a medication being studied for treating people with type 2 diabetes who also experience painful diabetic nerve damage. It is designed to be given as an injection under the skin once per week.

Semaglutide is a medication used to treat type 2 diabetes. It helps control blood sugar levels and is given as an injection under the skin once per week. It belongs to a class of medications called GLP-1 receptor agonists, which help the body produce more insulin when blood sugar levels are high.

CagriSema is a combination therapy that contains both cagrilintide and semaglutide in a single treatment. It is being studied as a weekly injection for people who have type 2 diabetes and painful diabetic nerve damage (diabetic peripheral neuropathy).

Type 2 diabetes – A chronic metabolic disorder where the body becomes resistant to insulin or doesn’t produce enough insulin to maintain normal blood sugar levels. The condition develops gradually, usually in adults, causing high blood sugar levels that can damage various body systems over time. The body either resists the effects of insulin or doesn’t produce sufficient insulin to maintain normal glucose levels.

Diabetic peripheral neuropathy – A nerve disorder that occurs as a complication of diabetes, causing damage to the nerves in the extremities, particularly the feet and legs. It typically begins with numbness, tingling, or burning sensations in the affected areas and can progress to cause varying degrees of pain. The condition develops gradually and can affect both sensory and motor nerves in the peripheral nervous system.